** U.S. shares of drug developer Atai Life Sciences 9VC.DE, ATAI.O rise 5.5% to $1.53 premarket
** Co, along with partner Beckley Psytech, reports results from mid-stage trial of its experimental treatment for alcohol use disorder
** Co says a single dose of the therapy, BPL-003, in combination with behavioral therapy shows sustained reduction in alcohol use and heavy drinking days up to 12 weeks
** The study enrolled 12 patients with the disorder - characterized by an impaired ability to stop or control alcohol use despite adverse health consequences
** BPL-003 was shown to be well-tolerated with no serious or severe adverse events reported
** Co anticipates reporting additional data from this study in publications and conferences later this year
** ATAI fell 5.6% in 2024
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.